(561) 000-0000 ยท info@stemcellmd.com West Palm Beach, FL

Treatments

Joint & Bone Conditions

The most extensively studied applications of BMAC โ€” supported by landmark clinical trials with multi-year follow-up data.

๐Ÿ’ช

Shoulder & Rotator Cuff

100% healing at 6 months vs. 67% surgery alone. 87% intact at 10 years vs. 44% in controls (Hernigou et al., 2014). BMA injected to tendon-bone junction during arthroscopic repair.

๐Ÿฆต

Knee Osteoarthritis

Statistically significant improvements in WOMAC pain, function, and VAS scores at 6 months (p<0.001) in 267 knees treated with a single Marrow Cellution BMA injection (Kuebler et al., 2022).

๐Ÿฆด

Hip โ€” AVN & Osteoarthritis

94% success in Stage I & II (Hernigou & Beaujean, 2002). Evidence of lesion size reduction and reversal of condition at 24 months (Gangji et al., 2004).

๐Ÿฆถ

Ankle & Talus Lesions

One-step arthroscopic technique combining BMA, autologous cancellous bone cores, and hyalofast membrane for osteochondral talus lesions (Becher et al.).

๐Ÿซ€

Elbow & Wrist

Targeted marrow delivery for chronic lateral epicondylitis, medial epicondylitis, and degenerative wrist conditions including TFCC injuries.

๐Ÿ”—

ACL & Ligament Injuries

BMA hydrates synthetic scaffold and packs bone tunnels in BPTB ACL reconstruction, improving graft integration and reducing donor-site morbidity (Scilia et al.).

๐Ÿฆฟ

Non-Union Fractures

88.3% bone union rate in 60 tibial non-union patients. Healing correlated with CFU count (>1,500/cc = 100% success). No complications (Hernigou et al., 2005).

๐Ÿฆต

Subchondral Insufficiency

Biologic subchondral augmentation using Marrow Cellution demonstrated as safe and effective for bone marrow lesions (BML) in the knee at 1-year follow-up (Gobbi et al., 2021).

๐Ÿฆถ

Plantar Fasciitis & Foot

Targeted percutaneous delivery to the plantar fascia insertion โ€” addressing the underlying degenerative pathology rather than masking symptoms.

Cervical & Lumbar Applications

๐Ÿ—๏ธ

Lumbar Fusion Augmentation

Cervos BMA delivers similar CFU doses as ICBG autograft without significant donor-site morbidity. Hydrates cancellous chips and synthetic graft for autograft-equivalent healing.

๐Ÿ—๏ธ

Cervical Disc Degeneration

BMA augmentation of cervical fusion procedures โ€” supporting bony incorporation while reducing the need for iliac crest bone graft harvest and associated complications.

๐Ÿ”ง

Non-Union at Fusion Sites

Percutaneous BMA injection to address failed or slow-healing fusion sites. Published literature supports efficacy in tibial shaft non-unions with CFU-count-dependent outcomes.

Beyond the Joint

๐Ÿงฌ

Erectile Dysfunction

Marrow Cellution delivers 3,160ยฑ297 CFU/mL vs. 506ยฑ102 for centrifuge. ED index 3ร— better for the Marrow Cellution group. BMA promotes vascular regeneration (Bieri et al., 2020).

๐Ÿซ€

Critical Limb Ischemia

Leg amputation rate in centrifuge group was 34.5% vs. 5.3% in Marrow Cellution group. Death rate 8.6% vs. 0%. Superior angiogenic outcomes (Mazzanti et al.).

๐Ÿ’“

Cardiac Applications (Research)

Animal and human studies have shown BM-MNC concentrate can contribute to therapeutic angiogenesis in ischemic cardiac tissue. Human trials ongoing.

Natural Rejuvenation

๐ŸŒฟ

Facial Rejuvenation

Autologous BMA-derived growth factors for facial volume restoration and skin texture improvement. 100% your own biology โ€” no synthetic fillers.

๐Ÿ’†

Scalp & Hair Regeneration

Emerging evidence supports BMA application at the scalp for hair follicle regeneration. Growth factors and EPCs promote vascularity and follicle health.

โœจ

Skin Regeneration & Scarring

Post-procedural healing acceleration and scar remodeling using autologous bone marrow concentrate applied topically or via micro-injection.

Ready to See If You’re a Candidate?

Schedule a free consultation โ€” we’ll review your condition and give you an honest assessment.

Book My Consultation